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Abstract: Coffee is widely consumed and contains many bioactive compounds, any of which may
impact pathways related to disease development. Our objective was to identify individual lipid
changes in response to coffee drinking. We profiled the lipidome of fasting serum samples collected
from a previously reported single blinded, three-stage clinical trial. Forty-seven habitual coffee
consumers refrained from drinking coffee for 1 month, consumed 4 cups of coffee/day in the
second month and 8 cups/day in the third month. Samples collected after each coffee stage were
subject to quantitative lipidomic profiling using ion-mobility spectrometry–mass spectrometry.
A total of 853 lipid species mapping to 14 lipid classes were included for univariate analysis.
Three lysophosphatidylcholine (LPC) species including LPC (20:4), LPC (22:1) and LPC (22:2),
significantly decreased after coffee intake (p < 0.05 and q < 0.05). An additional 72 species mapping to
the LPC, free fatty acid, phosphatidylcholine, cholesteryl ester and triacylglycerol classes of lipids
were nominally associated with coffee intake (p < 0.05 and q > 0.05); 58 of these decreased after coffee
intake. In conclusion, coffee intake leads to lower levels of specific LPC species with potential impacts
on glycerophospholipid metabolism more generally.
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1. Introduction
Coffee is one of the most widely consumed beverages in the world and has been implicated in
numerous diseases such as type 2 diabetes (T2D) and cardiovascular disease [1–4]. The causal and
precise molecular mechanisms that underlie the beneficial and adverse effects of coffee remain unclear.
Coffee is the major source of caffeine for many populations [5], but it also contains hundreds of other
compounds, many of which might impact pathways related to disease development or prevention [6].
High-throughput omic profiling techniques enable thorough studies of an individual’s response
to coffee intake and provide potentially new mechanistic insight to the role coffee plays in health [7,8].
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We recently performed a comprehensive metabolomics study of coffee consumption leveraging serum
samples collected during a coffee trial [8,9]. Over 100 metabolites were significantly associated
with coffee intake; several mapping to xanthine, benzoate, steroid, endocannabinoid and fatty acid
(acylcholine) metabolism. We extend this work to comprehensive lipid profiling for the first time.
Lipid molecules are a subset of the metabolome and serve as ubiquitous and essential multifunctional
metabolites [10]. Lipids are directly exposed to intracellular and extracellular biochemical changes and
as a result undergo various modifications themselves [10]. Our objective was to identify individual
lipid changes in response to coffee in order to gain more insight into biological mechanisms by which
coffee may impact health.
2. Subjects and Methods
2.1. Coffee Trial
Serum samples analyzed in the current study were obtained from participants completing an
investigator-blinded, three-stage controlled trial in 2009–2010 that lasted for 3 months (Supplementary
Note 1, ISRCTN registry: ISRCTN12547806) [9]. Briefly, habitual coffee consumers <65 years of age,
residing in Finland, free of T2D, but with an elevated risk of T2D were eligible for participation.
The participants received packages of coffee and brewed the coffee daily at home with their own
coffee machine using paper filters. During the first month, participants refrained from drinking coffee,
whereas in the second month they were instructed to consume 4 cups coffee/day (1 cup = 150 mL,
Juhla Mokka brand) and in the third month 8 cups/day. Of the 49 participants recruited, 47 completed
the trial. Baseline characteristics of these 47 participants are shown in Table S1. Several clinical
biomarkers were measured and analyzed as part of the initial report as previously described [9].
Serum concentrations of total cholesterol, High-density lipoprotein (HDL) cholesterol, apo A-I and
adiponectin increased significantly in response to coffee intake, whereas interleukin-18, 8-isoprostane,
and the ratios of low-density lipoprotein (LDL) to HDL cholesterol and of apo B and apo A-I decreased
significantly. The trial was conducted in accordance with the Declaration of Helsinki (1964), as amended
in South Africa (1996), and approved by Joint Authority for the Hospital District of Helsinki and
Uusimaa Ethics Committee, Department of Medicine, Helsinki, Finland. Written informed consent
was obtained from all participants.
2.2. Lipidomics Assay, Data Acquisition and Processing
Lipid species were measured in fasting serum samples collected after each coffee stage (True
Mass Complex Lipid Panel, Metabolon, Research Triangle Park, NC, USA). Lipids were extracted from
samples using dichloromethane and methanol in a modified Bligh-Dyer extraction in the presence
of internal standards with the lower, organic, phase being used for analysis. The extracts were
concentrated under nitrogen and reconstituted in 0.25 mL of dichloromethane:methanol (50:50)
containing 10 mM ammonium acetate. The extracts were placed in vials for infusion-mass spectrometry
(MS) analyses, performed on a SelexION equipped Sciex 5500 QTRAP using both positive and negative
mode electrospray. Each sample was subjected to two analyses, with ion mobility spectrometry
(IMS)-MS conditions optimized for lipid classes monitored in each analysis. The 5500 QTRAP
was operated in MRM mode to monitor the transitions for over 1100 lipids from up to 14 lipid
classes including cholesteryl esters (CE), triacylglycerols (TAG), diacylglycerols (DAG), free fatty
acids (FFA), phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylinositols
(PI), lysophosphatidylcholines (LPC), lysophosphatidylethanolamines (LPE), sphingomyelin (SM),
ceramide (CER), hexosylceramides (HCER), lactosylceramides (LCER), dihydroceramides (DCER).
Individual lipid species were quantified based on the ratio of signal intensity for target compounds to
the signal intensity for an assigned internal standard of known concentration. Missing values were
imputed with the observed minimum value. Individual lipid species that contained more than 20%
missing values across the first (0 cups/day) and third (8 cups/day) trial stages were not included for
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statistical analysis (120 lipid species, Table S2) leaving a total of 853 lipid species for analysis. The same
data, but with missing values treated as 0, were also expressed as mole% determined by calculating
the proportion of individual species within each class. In secondary analysis, lipid species data were
used to derive additional and biologically meaningful lipid traits. Lipid class concentrations were
calculated from the sum of all molecular species within a class. For lipid classes containing more than
one fatty acid (FA) per species (i.e., DAG, PC, PE, PI, and TAG) we also determined FA concentrations
by calculating the sum of individual FAs within each of these classes. These traits were derived prior
to excluding the lipids in Table S2 (see above). The final set of lipid species (primary traits) and derived
lipid traits (secondary) analyzed in the current study are listed in Table S3.
2.3. Statistical Analysis
All statistical analyses were performed using R, SAS version 9.4 (SAS Institute Inc, Cary, NC,
USA) or Matlab. To explore the data and identify any outlier samples we first performed standard
principal component analysis (PCA) and multilevel PCA [11]. For the latter, we generated a data
matrix of the within-person variation by subtracting individual lipid values from the mean lipid value
of all three coffee stages, per participant, per lipid. Repeated measures ANOVA was used to test
the relationship between coffee treatment and each individual lipid species. P-values were further
adjusted for multiple comparisons by the Benjamini–Hochberg procedure and the false discovery rate
(FDR)-adjusted P-values, expressed as q-values, are reported [12]. All nominal (p < 0.05) associations
are presented but only those with a q-value < 0.05 are defined as statistically significant. We computed
ordinary Pearson correlations to explore the latent relationships of changes in identified coffee lipids
across treatments. These analyses were additionally supplemented with data for metabolites and
clinical biomarkers that previously changed in response to coffee in this coffee trial (Table S4) [8,9].
Formal cross-platform integration analysis will be a focus of another report. Correlation networks
were constructed using Cytoscape [13]. In secondary analysis, lipid class and fatty acid concentrations
were also subject to univariate analysis. A multivariate approach was also pursued as traditionally
done with high-throughput data and is presented in Supplementary Note 2 and Figure S5.
3. Results
PCA or multilevel-PCA demonstrated no clear separation of samples by coffee stage (Figure S1).
As a result, no clear outliers were detected and thus all samples were included for our primary analysis.
Serum lipid class concentrations (data not shown) or distributions (Figure 1a) did not significantly
change in response to coffee intake. A total of 75 lipid species were at least nominally associated
with coffee intake and these mapped to 8 lipid classes (p < 0.05, Table 1, Figure 2a and Figure S2).
When applying an FDR correction, LPC 20:4, 22:1 and 22:2 remained significantly associated with coffee
intake (Figure 2b). Similar results were observed when lipid species concentrations were expressed as
mole% (Figure 1b and data not shown). When FA concentrations of DAG, PC, PE, PI, and TAG were
examined, no associations met statistical significance (data not shown).
Results of correlation analysis of changes among previously identified clinical [9] and
metabolite [8] markers of coffee response and the 75 nominal to significant lipid species identified
here (Table 1) are presented in Figure S3. Generally lipid species of the same class or sharing fatty
acid chains clustered together. Changes in TAGs that increased in response to coffee, however, did not
correlate with changes in TAGs that decreased in response to coffee. Changes in lipid species generally
correlated with metabolites that also decreased in response to coffee and thus unlikely originated
from the coffee beverage itself. These metabolites were also lipid derivatives; particularly those of the
acyl choline and endocannabinoid pathways. Besides kynurenine and xanthines, few other aqueous
metabolites were consistently represented among correlations with either clinical makers or lipid
species. No changes in lipids or metabolites were consistently correlated with clinical markers that
responded to coffee.
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Table 1. Significant lipid markers of coffee consumption *.
Lipid Class † Lipid Species
Group Effect Fold of Change §
p-Value q-Value 4 Cups/0 Cup 8 Cups/0 Cup 8 Cups/4 Cups
CE CE(20:4) 0.0296 0.4529 0.9 0.92 1.02
FFA(20:3) 0.0021 0.297 0.9 0.87 0.96
FFA(20:4) 0.0012 0.2492 0.95 0.87 0.91
FFA(22:2) 0.0481 0.4529 0.95 0.89 0.94FFA
FFA(22:6) 0.0415 0.4529 0.98 0.89 0.91
TAG47:1-FA17:0 0.0483 0.4529 1.26 1.4 1.11
TAG51:3-FA15:0 0.0401 0.4529 0.82 0.91 1.11
TAG52:4-FA16:1 0.0317 0.4529 0.8 0.92 1.15
TAG52:5-FA16:1 0.0329 0.4529 0.77 0.89 1.16
TAG52:5-FA20:5 0.05 0.4529 1.07 1.25 1.18
TAG52:6-FA16:1 0.041 0.4529 0.78 0.9 1.14
TAG53:3-FA16:0 0.0211 0.4529 0.88 0.87 1
TAG53:3-FA18:1 0.0242 0.4529 0.9 0.93 1.03
TAG53:4-FA16:0 0.0229 0.4529 0.84 0.89 1.07
TAG53:4-FA18:2 0.0289 0.4529 0.82 0.88 1.08
TAG53:5-FA18:3 0.048 0.4529 0.87 0.92 1.06
TAG54:3-FA18:1 0.0354 0.4529 0.82 0.9 1.09
TAG54:3-FA20:1 0.0368 0.4529 0.84 0.94 1.13
TAG54:4-FA20:1 0.0306 0.4529 0.82 0.94 1.14
TAG55:3-FA18:1 0.0353 0.4529 0.82 0.86 1.05
TAG55:4-FA18:1 0.0198 0.4529 0.82 0.85 1.04
TAG55:5-FA18:1 0.0208 0.4529 0.77 0.83 1.08
TAG56:3-FA18:1 0.0103 0.4529 0.81 0.87 1.07
TAG56:3-FA20:1 0.0155 0.4529 0.79 0.86 1.09
TAG56:4-FA18:1 0.0124 0.4529 0.8 0.87 1.08
TAG56:4-FA20:1 0.0314 0.4529 0.71 0.81 1.14
TAG56:4-FA20:2 0.0141 0.4529 0.84 0.88 1.05
TAG56:5-FA18:1 0.0221 0.4529 0.83 0.9 1.09
TAG56:5-FA20:2 0.0051 0.4529 0.77 0.84 1.08
TAG56:5-FA20:3 0.0215 0.4529 0.83 0.89 1.08
TAG56:5-FA20:4 0.0447 0.4529 0.84 0.91 1.07
TAG56:6-FA18:2 0.0132 0.4529 0.77 0.88 1.13
TAG56:6-FA20:2 0.0206 0.4529 0.76 0.84 1.11
TAG56:6-FA20:3 0.0077 0.4529 0.77 0.85 1.1
TAG56:6-FA20:4 0.0306 0.4529 0.81 0.88 1.08
TAG56:7-FA18:2 0.0457 0.4529 0.8 0.91 1.14
TAG56:7-FA20:3 0.042 0.4529 0.79 0.85 1.07
TAG56:7-FA22:4 0.0484 0.4529 0.87 0.92 1.06
TAG56:7-FA22:5 0.0384 0.4529 0.85 0.95 1.12
TAG56:9-FA20:4 0.0458 0.4529 0.83 0.92 1.11
TAG56:9-FA22:6 0.0229 0.4529 0.85 0.92 1.08
TAG57:8-FA22:6 0.0093 0.4529 0.87 0.91 1.04
TAG58:10-FA20:5 0.0161 0.4529 0.86 0.94 1.09
TAG58:10-FA22:5 0.0391 0.4529 0.74 0.84 1.14
TAG58:10-FA22:6 0.0388 0.4529 0.72 0.8 1.11
TAG58:7-FA22:4 0.0294 0.4529 0.81 0.89 1.11
TAG58:7-FA22:5 0.0109 0.4529 0.79 0.85 1.07
TAG58:8-FA20:4 0.0324 0.4529 0.85 0.9 1.06
TAG58:8-FA22:5 0.0386 0.4529 0.79 0.85 1.08
TAG58:9-FA22:5 0.0478 0.4529 0.78 0.86 1.1
TAG60:10-FA22:5 0.0349 0.4529 0.85 0.9 1.06
TAG60:10-FA22:6 0.0357 0.4529 0.82 0.92 1.13
TAG
TAG60:11-FA22:5 0.0038 0.4529 0.8 0.92 1.16
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Table 1. Cont.
Lipid Class † Lipid Species
Group Effect Fold of Change §
p-Value q-Value 4 Cups/0 Cup 8 Cups/0 Cup 8 Cups/4 Cups
LPC(15:0) 0.0142 0.4529 0.95 0.92 0.97
LPC(17:0) 0.0017 0.2886 0.96 0.9 0.93
LPC(18:1) 0.0423 0.4529 0.98 0.93 0.95
LPC(20:2) 0.0094 0.4529 0.95 0.89 0.93
LPC(20:3) 0.0362 0.4529 0.94 0.91 0.96
LPC(20:4) <0.0001 0.0088 0.94 0.87 0.93
LPC(22:1) <0.0001 0.0313 0.91 0.78 0.86
LPC
LPC(22:2) <0.0001 0.0051 0.94 0.79 0.84
PC(17:0/20:4) 0.0183 0.4529 0.91 0.91 1
PC(18:0/16:1) 0.0274 0.4529 1.09 1.3 1.19
PC(18:0/18:3) 0.0375 0.4529 1.13 1.24 1.1
PC(18:0/20:2) 0.0143 0.4529 1 1.11 1.11
PC(18:0/20:3) 0.0361 0.4529 0.96 1.08 1.12
PC
PC(18:1/20:4) 0.0152 0.4529 0.92 0.91 0.99
PE(18:0/20:1) 0.0203 0.4529 0.97 1.12 1.16
PE(O-16:0/18:2) 0.0301 0.4529 1.08 1.19 1.11
PE(O-18:0/20:3) 0.0458 0.4529 0.98 1.12 1.15
PE(P-16:0/18:2) 0.0246 0.4529 1.07 1.18 1.1
PE(P-16:0/22:4) 0.025 0.4529 0.89 1.01 1.14
PE
PE(P-18:0/18:2) 0.0406 0.4529 1.04 1.15 1.1
DCER DCER(24:0) 0.0475 0.4529 1 1.1 1.1
LCER LCER(26:1) 0.0097 0.4529 0.95 1.08 1.13
CE: cholesteryl ester; FFA: free fatty acid; TAG: triacylglycerol; LPC: lysophosphatidylcholine; PC: phosphatidylcholine;
PE: phosphatidylethanolamine; DCER: dihydroceramide; LCER: lactosylceramide. * Shown are results from RMA that
meet nominal significance (p < 0.05, column 3). Bold-faced lipid species meet significance threshold of p < 0.05 (column
3) and q < 0.05 (column 4). † neutral lipids: CE, FFA, TAG; phospholipids: LPC, PC, PE; sphingolipids: DCER, LCER.
§ ANOVA contrasts: lipid levels that increase in response to coffee are shaded red (p < 0.05) or pink (0.05 < p < 0.10) and
lipid levels that decrease are colored green (p < 0.05) or light green (0.05 < p < 0.10).
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4. Discussion
The current study is the first controlled trial-based lipidomic assessment of coffee intake. We found
three LPC species (LPC (20:4), LPC (22:1) and LPC (22:2)) that significantly decreased after 4 and 8 cups
per day. Several other species mapping to the LPC, FFA, PC and CE classes showed nominal but
plausible changes. Although the current lipid species analysis is unique from that of our previous
metabolomic analysis [8] of the same samples the findings taken together suggest that coffee drinking
has more of an immediate impact on non-lipid than lipid metabolites over the duration of the coffee
trial examined here.
The lipidomics platform was unable to distinguish between fatty acid isoforms, their position on
a glycerol backbone (i.e., sn-1 vs. sn-2) or define their bond type (acyl- or alkyl-). Several lipid species
at least nominally associated with coffee response contained FA(20:4). In our previous metabolomics
report [8], arachidonic acid (AA, 20:4n6) and LPC (20:4n6) were specifically measured and decreased
in response to coffee (p < 0.05, q < 0.05 for AA and p < 0.05, q > 0.05 for LPC (20:4n6)). These findings,
along with the correlation patterns among these lipid variables (Figure S3) suggest most contain the
n6 form of FA(20:4). The only relevant isoforms for FA(22:1) and FA(22:2) are 22:1n9 (erucic acid) and
22:2n6 (docosadienoic acid), respectively.
Figure S4 shows the biological relationships among the neutral and phospholipid lipid classes
measured in the current study. LPC is a bioactive phospholipid synthesized primarily from plasma
membrane- and lipoprotein-PC by phospholipase A1 (PLA1) or PLA2 that cleave the PC sn-1 or
sn-2 ester bond, respectively [14–16]. LPC can also be formed by lecithin cholesterol acyltransferase
in HDL, from oxidation of LDL and by endothelial lipase. LPC transports glycerophospholipid
components between tissues but is also a ligand for specific signaling receptors and activates several
second messengers [17]. Much experimental data have implicated LPC in atherosclerosis and
acute and chronic inflammation but results support both beneficial and adverse properties [18,19].
The conflicting biological properties of LPC might be due to their fatty acyl composition, with saturated
or monounsaturated LPC presenting with greater pro-atherogenic properties than polyunsaturated
LPCs [20–23]. In the current study, 18 of the 20 LPCs examined tended to decrease with coffee
intake but none of these shared a particular fatty acyl composition pattern (i.e., saturated or
polyunsaturated fatty acids) (Table 1 and data not shown). LPC(20:4n6) sn-2, a potential isoform of
LPC (20:4), is particularly interesting because it intersects several metabolic pathways that lead to the
production of potent signaling molecules such as 2-arachidonoyl-lysophosphatidic acid, and specific
eicosanoids and endocannabinoids [24–26]. Metabolites of the endocannabinoid system as well as
choline (a product of LPC metabolism) and glycerol-3-phosphate (a product of LPC metabolism
and endocannabinoid synthesis) significantly decreased in response to coffee intake in our previous
metabolomic study [8,18,27]. Interestingly, PLA2 also contributes to endocannabinoid synthesis [27].
Taken together, decreased LPC levels in response to coffee align with decreased levels of downstream
metabolites in similar biological pathways, most notably glycerophospholipid metabolism.
Although the caffeine component of coffee is known to stimulate lipolysis in the acute
setting [28–31], the mechanisms and constituents of habitual coffee drinking leading to decreased
LPC in the current study are unclear. The resistance of LDL to oxidative damage (a source of LPC)
in humans increases after consumption of coffee and this might be explained by the incorporation of
coffee’s phenolic acids into LDL [32]. Indeed, polyphenols, including those in coffee, decreased LPC
production induced by oxidation [33].
Population-based or cross-sectional metabolomic/lipidomic studies of self-reported habitual
coffee intake have also reported specific lipid species associated with coffee intake (Table S5).
Direct comparison with the current report is difficult given the study designs, different lipidomic
platforms used, and limitations in lipid species quantification (i.e., detected signals are usually a sum
of several isobaric/isomeric lipids). Interestingly, however, Miranda et al. [34] focused exclusively on
LPC species and found an inverse association between the plasma levels of LPC(16:1 a), LPC(18:1 a)
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and LPC(20:4 a) and habitual coffee intake, particularly when comparing intakes > 100 mL/day to
0 mL/day.
The uncertain biological implications of lower LPC levels also extends to human studies of
diseases or conditions of which are potentially modified by coffee consumption (Table S6). Most are
cross-sectional and include small sample sizes and generate some significant findings that are not
confirmed in other studies. Applicable to the original motivation of the data from our coffee trial
examined here is a recent meta-analysis of metabolite changes and risk of T2D [35]; only three lipid
markers were significantly associated with risk: LPC(18:0), SM(16:0) and FFA(18:1) [35]. None of these
lipid species changed in response to coffee in the current study.
All lipid species that potentially increased in response to coffee did so only after the period of
8 cups per day. These lipid species also tended to correlate among each other rather than with lipid
species that decreased in response to coffee, suggesting distinct lipid pathways altered by low and
high coffee intake. PC species were a notable exception. PC species that increased in response to
8 cups of coffee all contained FA(18:0) and their changes directly correlated with changes in LPCs,
TAGs, and acylcholines that decreased in response to 4 and 8 cups. This might suggest a shared lipid
pathway impacted by coffee intake and the increase in PC observed only after 8 cups per day is a
delayed dose response.
In the initial report of the current coffee trial, several clinical lipid and inflammatory biomarkers
changed in response to coffee [9]. None of these were convincingly correlated with lipids or metabolites
measured in the current or recent report and underscores additional information accessible via
high-throughput or more precise omic analysis. Triglycerides, for example, did not significantly
change in the trial, yet when analyzing TAG species we observed TAGs that potentially increased
and decreased in response to coffee. Nevertheless, a special complication in the analysis and clinical
interpretation of TAGs is the large number of isobars resulting from presence of different combinations
of the three acyl moieties and their regioisomers.
The application of lipidomics to a clinical study of coffee intake with repeated measures, large
contrasts in coffee intake, excellent participant compliance and standardized protocols for sample
handling and storage are major strengths of the current study. As a clinical trial it addresses many of the
limitations of observational studies. In addition, the composition of brewed coffee varies as a function
of bean type, roast and preparation methods; factors for which detailed information is rarely collected
in population-based studies of coffee. Participants of our clinical trial were all provided the same coffee:
a medium roast, 100% Arabica blend of Brazilian, Columbian, Central American and African coffee
which is a popular type of coffee in Finland. Despite these strengths, several weaknesses of the study
should be acknowledged. Our one-group study design without randomization, lack of blinding of
participants and placebo control were limitations. We cannot rule out an impact of time-varying factors
that may induce significant associations due to correlations with coffee. No specific guidelines were
provided on coffee additives (i.e., sugar, cream) or beverages to consume in the place of coffee during
the month of coffee abstinence. The very low levels of xanthine metabolites in the first month suggest
participants largely refrained from consuming any caffeine-containing beverages [8,9]. Our previous
report presented no obvious overlap with potential metabolite markers of dairy or tea consumption
or lifestyle factors [8]. Body weight, a proxy for energy balance, remained stable throughout the trial.
All participants for the current study were Finnish habitual coffee drinkers at increased risk of T2D
which may limit the generalizability of our findings to other groups.
5. Conclusions
Our study provides the first thorough analysis of the lipidomic changes in response to controlled
coffee consumption. The new findings suggest coffee alters glycerophospholipid metabolism and
build on our previous metabolomic results that yield novel candidate pathways that offer insight to
the mechanisms by which coffee may be exerting its health effects.
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